Go to Contents
ABOUT US
Company History
Jennerex
Contact Us
TECHNOLOGY
SOLVE ®
GEEV ®
Scientific Publications
PIPELINE
Development Pipeline
Pexa-Vec
(JX-594)
BAL0891
SJ-600 Series
JX-900 Series
PARTNERSHIP
Pexa-Vec
Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
Sillajen Sitemap
ABOUT US
Company History
Jennerex
Contact Us
TECHNOLOGY
SOLVE ®
GEEV ®
Scientific Publications
PIPELINE
Development Pipeline
Pexa-Vec (JX-594)
BAL0891
SJ-600 Series
JX-900 Series
PARTNERSHIP
Pexa-Vec Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
ENG
|
KOR
ENG
ENG
KOR
Targeting, Attacking, and Eradicating Cancers®
TOP
IR/PR
ABOUT US
TECHNOLOGY
PIPELINE
PARTNERSHIP
IR/PR
SillaJen Biotherapeutics
Publications & News
Publications & News
Stock Information
Financials
IR Inquiries
Publications & News
게시판
Total
28
. ˙
3
/
3
Page
Enter search terms
Run search button
8
SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
2016-01-06
7
SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco
2015-06-29
6
SillaJen Announces Agreement with the FDA for a Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
2015-04-20
5
Nature: Drug Development: Try and try again
2014-12-04
4
SillaJen Biotherapeutics To Present at the BIO Business Forum
2014-07-20
3
SillaJen Biotherapeutics Announces Completion of Name Change Following Acquisition of Jennerex
2014-07-19
2
SillaJen Announces Completion of Jennerex, Inc. Acquisition
2014-03-17
1
Bloomberg: Modified Smallpox Vaccine Stymies Liver Cancer in Study
2013-02-10
1
2
3
Targeting, Attacking, and Eradicating Cancers®
